Targeting the vasculature of colorectal carcinoma with a fused protein of (RGD)3 -tTF

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Huang, Zheng Jie ^a   Zhao, Yilin ^b   Luo, Wei Yuan ^a   You, Jun ^a   Li, Shui Wen ^a   Yi, Wen Cheng ^a   Wang, Sheng Yu ^b   Yan, Jiang Hua ^b   Luo, Qi ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

^b XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE GLYCINE ASPARTIC TRUNCATED TISSUE FACTOR FUSION PROTEIN; BLOOD CLOTTING FACTOR 10; HYBRID PROTEIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ANGIOGENESIS INHIBITOR; TTF RGD PEPTIDE; TTF-RGD PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG DISTRIBUTION; MALE; MOUSE; NONHUMAN; PROTEIN BINDING; SURVIVAL TIME; THROMBOSIS; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; C57BL MOUSE; COLORECTAL TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; TREATMENT OUTCOME; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; INTEGRIN ALPHAVBETA3; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 84880169150     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/637086     Document Type: Article

References (34)

1. Klotz L. V., Eichhorn M. E., Schwarz B., Seeliger H., Angele M. K., Jauch K.-W., Bruns C. J., Targeting the vasculature of visceral tumors: novel insights and treatment perspectives. Langenbeck's Archives of Surgery 2012 397 4 569 578 2-s2.0-84857948922 10.1007/s00423-012-0946-4
2. Danhier F., Breton A. L., Preat V., RGD-based strategies to target Alpha(v) Beta(3) integrin in cancer therapy and diagnosis. Molecular Pharmaceutics 2012 9 11 2961 2973
3. Lorenzon E., Colladel R., Andreuzzi E., Marastoni S., Todaro F., Schiappacassi M., Ligresti G., Colombatti A., Mongiat M., MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway. Oncogene 2012 31 3136 3147 10.1038/onc.2011.487 2-s2.0-80054762792 10.1038/onc.2011.487
4. Siemann D. W., Chaplin D. J., Horsman M. R., Vascular-targeting therapies for treatment of malignant disease. Cancer 2004 100 12 2491 2499 2-s2.0-2642571660 10.1002/cncr.20299
5. Baguley B. C., Antivascular therapy of cancer: DMXAA. The Lancet Oncology 2003 4 3 141 148 2-s2.0-0037341637 10.1016/S1470-2045(03)01018-0
6. Daubie V., Pochet R., Houard S., Philippart P., Tissue factor: a mini-review. Journal of Tissue Engineering and Regenerative Medicine 2007 1 3 161 169 2-s2.0-41949088161 10.1002/term.9
7. Chen X., Lv H., Ye M., Wang S., Ni E., Zeng F., Cao C., Luo F., Yan J., Novel superparamagnetic iron oxide nanoparticles for tumor embolization application: preparation, characterization and double targeting. International Journal of Pharmaceutics 2012 426 1-2 248 255 2-s2.0-84857790336 10.1016/j.ijpharm.2012.01.043
8. Kessler T., Bieker R., Padró T., Schwöppe C., Persigehl T., Bremer C., Kreuter M., Berdel W. E., Mesters R. M., Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clinical Cancer Research 2005 11 17 6317 6324 2-s2.0-24344462235 10.1158/1078-0432.CCR-05-0389
9. Guan M., Su B., Ye C., Lu Y., Production of extracellular domain of human tissue factor using maltose-binding protein fusion system. Protein Expression and Purification 2002 26 2 229 234 2-s2.0-0036417348 10.1016/S1046-5928(02) 00537-5
10. Bieker R., Kessler T., Schwöppe C., Padró T., Persigehl T., Bremer C., Dreischalück J., Kolkmeyer A., Heindel W., Mesters R. M., Berdel W. E., Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood 2009 113 20 5019 5027 2-s2.0-66549114936 10.1182/blood-2008-04-150318
11. Huang X., Molema G., King S., Watkins L., Edgington T. S., Thorpe P. E., Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997 275 5299 547 550 2-s2.0-0031026481 10.1126/science.275.5299.547
12. Huang X., Ding W.-Q., Vaught J. L., Wolf R. F., Morrissey J. H., Harrison R. G., Lind S. E., Asoluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties. Blood 2006 107 3 980 986 2-s2.0-31544434253 10.1182/blood-2005-07-2733
13. Ghose S., Hubbard B., Cramer S. M., Binding capacity differences for antibodies and Fc-fusion proteins on protein A chromatographic materials. Biotechnology and Bioengineering 2007 96 4 768 779 2-s2.0-33947138076 10.1002/bit.21044
14. Zitt M., Untergasser G., Amberger A., Moser P., Stadlmann S., Zitt M., Müller H. M., Mühlmann G., Perathoner A., Margreiter R., Gunsilius E., Öfner D., Dickkopf-3 as a new potential marker for neoangiogenesis in colorectal cancer: expression in cancer tissue and adjacent non-cancerous tissue. Disease Markers 2008 24 2 101 109 2-s2.0-38349133630
15. Goel S., Duda D. G., Xu L., Munn L. L., Boucher Y., Fukumura D., Jain R. K., Normalization of the vasculature for treatment of cancer and other diseases. Physiological Reviews 2011 91 3 1071 1121 2-s2.0-79960096827 10.1152/physrev.00038.2010
16. Shantha Kumara H. M. C., Tohme S. T., Herath S. A. C., Yan X., Senagore A. J., Nasar A., Kalady M. F., Baxter R., Whelan R. L., Plasma soluble vascular adhesion molecule-1 levels are persistently elevated during the first month after colorectal cancer resection. Surgical Endoscopy 2012 26 6 1759 1764 2-s2.0-84855211331 10.1007/s00464-011-2112-4
17. Saad R. S., Liu Y. L., Nathan G., Celebrezze J., Medich D., Silverman J. F., Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Modern Pathology 2004 17 2 197 203 2-s2.0-4344658425 10.1038/modpathol.3800034
18. Su Z.-F., Liu G., Gupta S., Zhu Z., Rusckowski M., Hnatowich D. J., In vitro and in vivo evaluation of a technetium-99m-labeled cyclic RGD peptide as a specific marker of α v β 3 integrin for tumor imaging. Bioconjugate Chemistry 2002 13 3 561 570 2-s2.0-0036000149 10.1021/bc0155566
19. Mousa S. A., Mohamed S., Wexler E. J., Kerr J. S., Antiangiogenesis and anticancer efficacy of TA138, a novel α v β 3 antagonist. Anticancer Research 2005 25 1 197 206 2-s2.0-16344371198
20. Cai H., Li Z., Huang C.-W., Park R., Conti P. S., 64Cu labeled ambasar-RGD2 for micro-PET imaging of integrin α v β 3expression. Current Radiopharmaceuticals 2011 4 1 68 74 2-s2.0-79955685696
21. Haubitz M., Brunkhorst R., Influence of a novel rapamycin analogon SDZ RAD on endothelial tissue factor and adhesion molecule expression. Transplantation Proceedings 2002 34 4 1124 1126 2-s2.0-0035998992 10.1016/S0041-1345(02)02763-X
22. Lwaleed B. A., Bass P. S., Tissue factor pathway inhibitor: structure, biology and involvement in disease. Journal of Pathology 2006 208 3 327 339 2-s2.0-32244438720 10.1002/path.1871
23. Fonseca M. J., Haisma H. J., Klaassen S., Vingerhoeds M. H., Storm G., Design of immuno-enzymosomes with maximum enzyme targeting capability: effect of the enzyme density on the enzyme targeting capability and cell binding properties. Biochimica et Biophysica Acta 1999 1419 2 272 282 2-s2.0-0033042189 10.1016/S0005-2736(99)00073-5
24. Chen K., Chen X., Integrin targeted delivery of chemotherapeutics. Theranostics 2011 1 189 200
25. Xiong J.-P., Stehle T., Zhang R., Joachimiak A., Frech M., Goodman S. L., Arnaout M. A., Crystal structure of the extracellular segment of integrin α V β 3 in complex with an Arg-Gly-Asp ligand. Science 2002 296 5565 151 155 2-s2.0-0037023363 10.1126/science.1069040
26. Papo N., Silverman A. P., Lahti J. L., Cochran J. R., Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and α v β 3 integrin. Proceedings of the National Academy of Sciences of the United States of America 2011 108 34 14067 14072 2-s2.0-80052184184 10.1073/pnas.1016635108
27. Kok R. J., Schraa A. J., Bos E. J., Moorlag H. E., Á sgeirsdóttir S. A., Everts M., Meijer D. K. F., Molema G., Preparation and functional evaluation of RGD-modified proteins as α v β 3 integrin directed therapeutics. Bioconjugate Chemistry 2002 13 1 128 135 2-s2.0-0036007606 10.1021/bc015561+
28. Schwöppe C., Kessler T., Persigehl T., Liersch R., Hintelmann H., Dreischalück J., Ring J., Bremer C., Heindel W., Mesters R. M., Berdel W. E., Tissue-factor fusion proteins induce occlusion of tumor vessels. Thrombosis Research 2010 125 S143 S150 2-s2.0-77955493301
29. Hu P., Yan J., Sharifi J., Bai T., Khawli L. A., Epstein A. L., Comparison of three different targeted Tissue Factor fusion proteins for inducing tumor vessel thrombosis. Cancer Research 2003 63 16 5046 5053 2-s2.0-0042014566
30. 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. Journal of Biological Chemistry 2000 275 31 23745 23750 2-s2.0-0034604650 10.1074/jbc.C000186200
31. Kolvunen E., Wang B., Ruoslahti E., Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Bio/Technology 1995 13 3 265 270 2-s2.0-0028899525
32. Carron C. P., Meyer D. M., Engleman V. W., Rico J. G., Ruminski P. G., Ornberg R. L., Westlin W. F., Nickols G. A., Peptidomimetic antagonists of α v β 3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone. Journal of Endocrinology 2000 165 3 587 598 2-s2.0-0033625260
33. Stewart P. L., Chiu C. Y., Huang S., Muir T., Zhao Y., Chait B., Mathias P., Nemerow G. R., Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization. EMBO Journal 1997 16 6 1189 1198 2-s2.0-0031003549 10.1093/emboj/16.6.1189
34. Temming K., Schiffelers R. M., Molema G., Kok R. J., RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resistance Updates 2005 8 6 381 402 2-s2.0-33644827912 10.1016/j.drup.2005.10.002